On November 3, 2022 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reported that its leukemia research program on OSE-127 has been selected for an oral presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting (New Orleans, Louisiana; December 10 – 13, 2022) (Press release, OSE Immunotherapeutics, NOV 3, 2022, View Source [SID1234646952]). This upcoming presentation has received the merit-based "Abstract Achievement Award" from the peerreview committee.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: "We are honored by the recognition and the interest in the quality of our research in Leukemia from the prestigious American Society of Hematology (ASH) (Free ASH Whitepaper). This award is the result of our fruitful collaboration with the University of Kiel evaluating, in patient-derived xenograft models, the therapeutic potential of OSE-127 in targeting and blocking the high and dysregulated IL-7 receptor-expression observed in more than 80% of B- or T-Acute Lymphoblastic Leukemia (ALL) patients".
Pr. Denis Schewe (Head of the Pediatrics Department, Otto-von-Guericke-University, Magdeburg and formerly from the University Medical Center Schleswig-Holstein of Kiel) and Dr. Lennart Lenk (Department of Pediatrics I, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel), leading the research program in collaboration with OSE Immunotherapeutics, say: "Acute lymphoblastic leukemia is a very aggressive tumor arising from B or T cells precursors (B- and T-ALL, respectively). Relapse remains a clinical challenge in B-ALL in highrisk patients and treatment options for T-ALL remain very limited. Novel targeted immunotherapy approaches are urgently needed to prevent relapse and to treat refractory diseases in ALL patients".
The global intellectual property for OSE-127 has been further strengthened, based on a unique and innovative dual anti-leukemic mechanism of action. This antibody both blocks oncogenic interleukin-7 fuel pathway and simultaneously triggers macrophage-driven phagocytosis of leukemic cells. Additional patent applications were filed in 2021 and 2022 covering the use of anti-IL-7 receptor antagonist antibodies with macrophage-redirected phagocytic activity for the targeted treatment of IL-7 receptor-positive cancers.
Furthermore, OSE-127 is currently being developed in clinical stage in partnership with Servier. Two clinical studies are ongoing in inflammatory diseases: a phase 2a study conducted in primary Sjögren’s syndrome by Servier and a phase 2 study conducted in ulcerative colitis by OSE Immunotherapeutics.
About Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is a heterogeneous group of lymphoid disorders resulting from clonal proliferation of immature lymphocytes of B-cell (85%) or T-cell (15%) lineages(1) in the blood, bone marrow, and other lymphoid organs.
Although it is one of the most common cancers in children, accounting for approximately 25% of all
childhood cancer diagnoses among children under 15 years of age (2), adults can also develop ALL.
About 40% cases of ALL diagnosed are in adults and among them about 50% present refractory disease
or undergo relapse under current conventional therapies(2)